JL I agree with you but have a slightly different reading of the tea leaves.
Yes absolutely avoid another stock holder law suit when discussing Reduce-it completion.
I am thinking by what was stated today that the label changed is more probable by December, which is exactly what Lovaza got with out running a trial and a great way to fend off Fibrates and Niacin for Anchor population.
Why press the FDA for the SPA to be reinstated by December when it can and will be brought up at interim. Possibly only a few more months away and possibly a provision of the settlement with the FDA?
Reduce-it trial enrollment was tracking at 100 per quarter, but now they are going to enroll the last 200 or so by the end of the year. Hmmmm, why the speed up if you think interim will not occur until second quarter 2016? I would think they want the trial fully enrolled before interim, and this may signal interim will come in the first quarter like HD predicted, also this may be a provision of the settlement with the FDA?
I will state this again as I was poo-pooed by sts66 about more partnerships/contracts being to difficult to clean up if bought out by a BP. The company stated they are still in talks and I am sure dragging there feet until interim, which will possibly make for much more lucrative contracts. Also may occur in first quarter of 2016 as previously stated.
These goals all seem attainable by December and first quarter 2016, and would be quite a savy move for a level headed management team.
